<DOC>
	<DOCNO>NCT00181922</DOCNO>
	<brief_summary>The objective study compare safety effectiveness Ziprasidone treatment mania child adolescent Bipolar disorder 8 week . This exploratory , open-label study , seek determine evidence efficacy . The result study used generate hypothesis large study .</brief_summary>
	<brief_title>Ziprasidone Treatment Mania Children Adolescents With Bipolar Disorder</brief_title>
	<detailed_description>Initial clinical evidence suggest atypical neuroleptic may play unique therapeutic role management symptom youth bipolar disorder . Ziprasidone class atypical neuroleptic unique pharmacological profile include D2 5HT2 antagonistic effect . This combined dopaminergic serotonergic activity seem associate antipsychotic effect also mood stabilize , mood elevate anti-aggressive effect well low risk extrapyramidal symptom tardive dyskinesia . Ziprasidone particular find high 5HT2A D2 receptor affinity ratio , suggest likelihood extrapyramidal symptom hyperprolactinemia may decrease . This make ideal candidate treat mania child , although use clinical practice , adequate data collect safety effectiveness . This study include 1 ) 8-week acute period , participant observe weekly visit , 10-month extension period , participant saw study clinician monthly basis , document response rate 2 ) assessment impact Ziprasidone functional capacity ( quality life , psychosocial function ) cognition , 3 ) careful assessment safety tolerability .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>1 . Males females age 6 18 year age 2 . Parent legal representative must level understanding sufficient communicate intelligently investigator study coordinator , cooperate test examination require protocol . 3 . Patients legal representative must consider reliable . 4 . Each patient his/her authorized legal representative must understand nature study . The patient 's authorized legal representative must sign informed consent document . 5 . Patient must diagnosis bipolar I bipolar II disorder currently display acute manic , hypomanic , mixed episode ( without psychotic feature ) accord DSMIV base clinical assessment confirm structured diagnostic interview ( Kidd Schedule Affective Disorders ) . 6 . Patients must initial score YMRS total score least 15 . 7 . Patient must able participate mandatory blood draw . 8 . Patient must able swallow pill . 1 . Patients chronic medical illness , DSMIV substance dependence within past 6 month , pregnant nursing female , serious risk suicide exclude study 2. investigator his/her immediate family ; define investigator 's spouse , parent , child , grandparent , grandchild . 3 . Serious unstable illness include hepatic , renal , gastroenterologic , respiratory , cardiovascular ( include ischemic heart disease ) , endocrinologic , neurologic , immunologic , hematologic disease . 4 . Known history QT prolongation ( ie . Congenital long QT syndrome ) , cardiac arrhythmia , recent myocardial infarction , heart failure 5 . Concurrent medication know prolong QT interval include : antiarrhythmic ( quinidine ) , antimicrobial antimalarial ( erythromycin , clarithromycin , ketoconazole , sparfloxacin , moxifloxacin , levofloxacin , gatifloxacin , chloroquine ) antihistamine ( diphenhydramine , hydroxyzine ) . 6 . Known hypokalemia hypomagnesemia 7 . Uncorrected hypothyroidism hyperthyroidism 8 . History severe allergy multiple adverse drug reaction 9 . Nonfebrile seizure without clear resolve etiology 10 . Leukopenia history leucopenia without clear resolve etiology 11 . DSMIV substance ( except nicotine caffeine ) dependence within past 6 month 12 . Judged clinically serious suicidal risk 13 . Any concomitant medication primarily central nervous system activity specify Concomitant Medication portion protocol 14 . History intolerance Ziprasidone determine principal investigator . 15 . Treatment irreversible monoamine oxidase inhibitor within 2 week prior visit 2 16 . Current diagnosis schizophrenia 17 . For concomitant stimulant therapy use treat ADHD , patient must stable dose medication 1 month prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>bipolar disorder</keyword>
	<keyword>child</keyword>
	<keyword>ziprasidone</keyword>
	<keyword>mania</keyword>
</DOC>